Abstract

Arabinosyleytosine (1-β-D-arabinofuranosylcytosine; cytosine arabinoside; cytosar; ara-C; cytarabine) is a member of a class of nucleosides in which D-arabinose constitutes the pentose sugar moiety. Thus, these compounds are analogs of ribo- nucleosides in which the hydroxyl group at the 2’-position is inverted. However, in most respects the arabinosides do not behave biologically as ribonucleoside analogs. Certain arabinosides are naturally occurring, both arabinosylthymine and arabinosyluracil (ara-U) having been isolated from the sponge Cryptotethya crypta, (Bergman and Feeney, 1951; Bergman and Burke, 1955). Cohen (1963) has reviewed some aspects of the occurrence, isolation, and relevance to chemotherapy of the arabinosides, and suggested a possible role for these nucleosides in aging. The same author in a later review (Cohen, 1966) has outlined methods for chemical synthesis of these compounds, the metabolism of ara-C and ara-U in bacteria, and some effects of the arabinosides on mammalian cells. Much of the pharmacological information regarding ara-C that was available through 1968 may be found briefly reviewed in an article on cancer chemotherapy by Sartorelli and Creasey (1969). Clinical brochures that include some information about the chemistry, antitumor activity in experimental systems, and preliminary data obtained in man, have been prepared by Livingston and Carter (1968) and the Upjohn Company (1970). Notari et al. (1972) have defined the stability of the drug under various storage conditions and found that at neutral pH the drug retains 90% of its potency after 6 months at room temperature.

Keywords

Triphosphate Uracil Vaccinia Camptothecin BCNU 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahearn, M. J., Lewis, C. W., Campbell, L. A., Luce, J. K.: Nuclear bleb formation in human bone marrow cells during cytosine arabinoside therapy. Nature (Lond.) 215, 196–197 (1967).Google Scholar
  2. Atkinson, C., Stacey, K. A.: Thymineless death induced by cytosine arabinoside. Biochim. biophys. Acta (Amst.) 166, 705–707 (1968).Google Scholar
  3. Bach, M. K.: Biochemical and genetic studies of a mutant strain of mouse leukemia L1210 resistant to 1 -β-D-arabinof uranosyl cytosine (cytarabine) hydrochloride. Cancer Res. 29, 1036–1044 (1969).PubMedGoogle Scholar
  4. Bader, J. P.: Metabolic requirements for infection by Rous sarcoma virus. I. The transient requirement for DNA synthesis. Virology 29, 444 451 (1966).Google Scholar
  5. Baguley, B. C., Falkenhaug, E. M.: Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia. Cancer Chemother. Rep. 55, 291–298 (1971).Google Scholar
  6. Baldini, L., Brambilla, G., Cavanna, M., Parodi, S.: Immunosuppressive activity of methotrexate and arabinosylcytosine in mice bearing L1210 leukemia. Brit. J. Pharmacol. 34, 674P–676P (1968).Google Scholar
  7. Bell, E.: Informational DNA synthesis distinguished from that of nuclear DNA by inhibitors of DNA synthesis. Science 174, 603–606 (1971).PubMedGoogle Scholar
  8. Bell, W. R., Whang, J. J., Carbone, P. P., Brecher, G., Block, J. B.: Cytogenetic and morphologic abnormalities in human bone marrow cells during cytosine arabinoside therapy. Blood 27, 771–781 (1966).PubMedGoogle Scholar
  9. Benedict, W. P., Harris, N., Karon, M.: Kinetics of 1-β-D-arabinofuranosy Icytosine -induced chromosome breaks. Cancer Res. 30, 2477–2483 (1970).PubMedGoogle Scholar
  10. Benedict, W. F., Karon, M.: Chromatid breakage: cytosine arabinoside-induced lesions inhibited by UV irradiation. Science 171, 680–682 (1971).PubMedGoogle Scholar
  11. Ben-Porat, T., Brown, Mc K., Kaplan, A. S.: Effect of 1-β-D-arabinofuranosylcytosine on DNA synthesis. II. In rabbit kidney cells infected with herpes viruses. Molec. Pharmacol. 4, 139–146 (1968).Google Scholar
  12. Bergmann, W., Burke, D. C.: Contributions to the study of marine products. XXXIX. The nucleosides of sponges. III. Spongothymidine and spongouridine. J. org. Chem. 20, 1501 –1507 (1955).Google Scholar
  13. Bergmann, W., Feeney, R. J.: Contributions to the study of marine products. XXXII. The nucleosides of sponges. I. J. org. Chem. 16, 981–987 (1951).Google Scholar
  14. Block, J. B., Bell, W., Whang, J., Carbone, P. P.: Hematologic and cytogenetic abnormalities during cytosine arabinoside (CA) therapy. Proc. Amer. Ass. Cancer Res. 6, 6 (1965).Google Scholar
  15. Bors A, J., Whitmore, G. F., Valeriote, F. A., Collins, D., Bruce, W. R.: Studies on the persistence of methotrexate, cytosine arabinoside and leukovorin in the serum of mice. J. nat. Cancer Institute 42, 235–242 (1969).Google Scholar
  16. Borun, T. W., Scharff, M. D., Robbins, E.: Rapidly labeled, polyribosome-associated RNA having the properties of histone messenger. Proc. nat. Acad. Sci. (Wash.) 58, 1977–1983 (1967).Google Scholar
  17. Bremerskov, V., Kaden, P., Mittermayer, C.: DNA synthesis during the life cycle of L cells: morphological, histochemical and biochemical investigations with arabinosylcytosine and thioarabinosylcytosine. Europ. J. Cancer 6, 379–392 (1970).Google Scholar
  18. Brewen, J. G.: The induction of chromatid lesions by cytosine arabinoside in post-DNA synthetic human leukocytes. Cytogenetics 4, 28–36 (1965).Google Scholar
  19. Brewen, J. G., Christie, N. T.: Studies on the induction of chromosomal aberrations in human leukocytes by cytosine arabinoside. Exp. Cell Res. 46, 276–291 (1967).PubMedGoogle Scholar
  20. Burchenal, J. H., Wiggins, R., Butterbaugh, J.: Activity of iN4-ydroxyl derivatives of 1-β-D-arabinofuranosylcytosine (ara-C) in Burkitt cell culture and mouse leukemia. Proc. Amer. Ass. Cancer Res. 8, 8 (1967).Google Scholar
  21. Buskirk, H. H., Crim, J. A., Petering, H. G., Merritt, K., Johnson, A. G.: Effect of uracil mustard and several antitumor drugs on the primary antibody response in rats and mice. J. nat. Cancer Inst. 34, 747–758 (1965).PubMedGoogle Scholar
  22. Buthala, D. A.: Cell culture studies on antiviral agents: 1-Action of cytosine arabinoside and some comparisons with 5-iodo-2’-deoxyuridine. Proc. Soc. Exp. Biol. (N.Y.) 115, 69 77 (1964).Google Scholar
  23. Calabresi, P., Creasey,W. A., Prusoff, W. H., Welch, A. D.: Clinical and pharmacological studies with 5-iodo-2’-deoxycytidine. Cancer Res. 23, 583–592 (1963).Google Scholar
  24. Camiener, G. W.: Studies of the enzymatic deamination of cytosine arabinoside. II. Properties of the deaminase of human liver. Biochem. Pharmacol. 16, 1681–1689 (1967a).PubMedGoogle Scholar
  25. Camiener, G. W.: Studies of the enzymatic deamination of cytosine arabinoside. III. Substrate requirements and inhibitors of the deaminase of human liver. Biochem. Pharmacol. 16, 1691–1702 (1967 b).Google Scholar
  26. Camiener, G. W., Smith, C. G.: Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem. Pharmacol. 14, 1405–1416 (1965).PubMedGoogle Scholar
  27. Camiener, G. W., Smith, C. G.: Studies of the enzymatic deamination of aracytidine. V. Inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides. Biochem. Pharmacol. 17, 1981–1991 (1968).PubMedGoogle Scholar
  28. Cardeilhac, P. T., Cohen, S. S.: Some metabolic properties of nucleotides of 1-β-D-arabino-furanosylcytosine. Cancer Res. 24, 1595–1603 (1964).PubMedGoogle Scholar
  29. Chaube, S., Kreis, W., Uchida, K., Murphy, M. L.: The teratogenic effect of 1-β-D-arabino- furanosylcytosine in the rat. Protection by deoxycytidine. Biochem. Pharmacol. 17, 1213 –1226 (1968).PubMedGoogle Scholar
  30. Chu, M. Y.: Incorporation of arabinosylcytosine into 2–7 S ribonucleic acid and cell death. Biochem. Pharmacol. 20, 2057–2063 (1971).PubMedGoogle Scholar
  31. Chu, M. Y., Fischer, G. A.: A proposed mechanism of action of 1 -β-D-arabin of uranosylcytosine as an inhibitor of the growth of leukemic cells. Biochem. Pharmacol. 11, 423–430 (1962).PubMedGoogle Scholar
  32. Chu, M.Y., Fischer, G. A.: Comparative studies of leukemic cells sensitive and resistant to cytosine arabinoside. Biochem. Pharmacol. 14, 333–341 (1965).PubMedGoogle Scholar
  33. Chu, M. Y., Fischer, G. A.: Effects of cytosine arabinoside on the cell viability and uptake of deoxypyrimidine nucleosides in L5178 Y cells. Biochem. Pharmacol. 17, 741–751 (1968a).PubMedGoogle Scholar
  34. Chu, M. Y., Fischer, G. A.: The incorporation of 3H-cytosine arabinoside and its effect on murine leukemic cells (L5178Y). Biochem. Pharmacol. 17, 753–767 (1968b).PubMedGoogle Scholar
  35. Cleaver, J. E.: Repair replication and degradation of bromouracil-substituted DNA in mammalian cells after irradiation with ultraviolet light. Biophys. J. 8, 775–791 (1968).PubMedGoogle Scholar
  36. Cline, M. J.: Prediction of in vivo cytotoxicity of chemotherapeutic agents by their effect on malignant leukocytes in vitro. Blood 30, 176–188 (1967).PubMedGoogle Scholar
  37. Cline, M. J., Rosenbaum, E.: Prediction of in vivo cytotoxicity of chemotherapeutic agents by their in vitro effect on leukocytes from patients with acute leukemia. Cancer Res. 28, 2516–2521 (1968).PubMedGoogle Scholar
  38. Cohen, S. S.: Sponges, cancer chemotherapy and cellular aging. Perspect. biol. Med. 6, 215–227 (1963).Google Scholar
  39. Cohen, S. S.: Introduction to the biochemistry of D-arabinosyl nucleotides. Progr. nucleic Acid Res. 5, 1–88 (1966).Google Scholar
  40. Colby, C., Edlin, G.: Nucleotide pool levels in growing, inhibited, and transformed chick fibroblast cells. Biochemistry 9, 917–920 (1970).PubMedGoogle Scholar
  41. Creasey, W. A.: Studies on the metabolism of 5-iodo-2’-deoxycytidine in vitro. J. biol. Chem. 238, 1772–1776 (1963).PubMedGoogle Scholar
  42. Creasey, W. A., Deconti, R. C., Kaplan, S. R.: Biochemical studies with 1 -β-D-arabinofurano-sylcytosine in human leukemic leukocytes and normal bone marrow cells. Cancer Res. 28, 1074–1081 (1968).PubMedGoogle Scholar
  43. Creasey, W. A., Flanigan, S., Mccollum, R. W., Calabresi, P.: Intraventricular administration of antimetabolites in patients with neoplasms and infections of the CNS. Proc. Amer. Ass. Cancer Res. 9, 16 (1968).Google Scholar
  44. Creasey, W. A., Papac, R. J., Markiw, M. E., Calabresi, P., Welch, A. D.: Biochemical and pharmacological studies with 1-β-D-arabinofuranosylcytosine in man. Biochem. Pharmacol. 15, 1417–1428 (1966).PubMedGoogle Scholar
  45. Cummings, D. J.: Comments on “thymineless death induced by cytosine arabinoside”. Bio-chim. biophys. Acta (Amst.) 179, 237–238 (1969).Google Scholar
  46. Dabżynkiewicz, E., Kuśwerek, J. T., Shugar,D.: o’-Methyl derivatives of arabinosylcytosine. Biochem. biophys. Res. Commun. 46, 1734–1741 (1972).Google Scholar
  47. Dixon, R. L., Adamson, R. H.: Antitumor activity and pharmacologic disposition of cytosine arabinoside (NSC 63878). Cancer Chemother. Rep. 48, 11–16 (1965).Google Scholar
  48. Doering, A., Keller, J., Cohen, S. S.: Some effects of D-arabinosylnucleosides on polymer synthesis in mouse fibroblasts. Cancer Res. 26, 2444–2450 (1966).PubMedGoogle Scholar
  49. Dollinger, M. R., Burchenal, J. H., Kreis, W., Pox, J. J.: Analogs of 1-β-D-arabinofuranosyl- cytosine. Studies on mechanisms of action in Burkitt’s cell culture and mouse leukemia, and in vitro deamination studies. Biochem. Pharmacol. 16, 689–706 (1967).PubMedGoogle Scholar
  50. Dollinger, M., Kreis, W., Stoll, D., Fox, J., Burchenal, J. H.: Deamination of cytosine arabinoside and its analogs. Proc. Amer. Ass. Cancer Res. 8, 14 (1967).Google Scholar
  51. Drahovsky, D., Kreis, W.: Studies on drug resistance-II. Kinase patterns in P815 neoplasms sensitive and resistant to 1 -β-D-arabinofuranosylcytosine. Biochem. Pharmacol. 19, 940 –944 (1970).PubMedGoogle Scholar
  52. Durham, J. F., Ives, D. H.: Feedback control of calf thymus deoxycytidine kinase. Fed. Proc. 26, 808 (1967).Google Scholar
  53. Durham, J. P., Ives, D. H.: Deoxycytidine kinase. 1. Distribution in normal and neoplastic tissues and inter-relationships of deoxycytidine and 1-β-D-arabinof uranosylcy tosine phosphorylation. Molec. Pharmacol. 5, 358–375 (1969).Google Scholar
  54. Evans, J. S., Bostwick, L., Mengel, G. D.: Synergism of the antineoplastic activity of cytosine arabinoside by porfiromycin. Biochem. Pharmacol. 13, 983–988 (1964).PubMedGoogle Scholar
  55. Evans, J. S., Mengel, G. D.: The reversal of cytosine arabinoside activity in vivo by deoxycytidine. Biochem. Pharmacol. 13, 989–994 (1964).PubMedGoogle Scholar
  56. Evans, J. S., Musser, E. A., Bostwick, L., Mengel, G. D.: The effect of 1-β-D-arabinofuranosyl- cytosine hydrochloride on murine neoplasms. Cancer Res. 24, 1285–1293 (1964).PubMedGoogle Scholar
  57. Evans, J. S., Musser, E. A., Mengel, G. D., Forsblad, K. R., Hunter, J. H.: Antitumor activity of 1 -β-D-arabinofuranosylcytosine hydrochloride. Proc. Soc. exp. Biol. (N.Y.) 106, 350–353 (1961).Google Scholar
  58. Fahmy, O. G., Fahmy, M. J., De Vrye, C. E.: The mutagenic properties of the nucleosides of pyrimidine analogues in Drosophilia melanogaster. Biochem. Pharmacol. 15, 299–316 (1966).PubMedGoogle Scholar
  59. Falco, E. A., Fox, J. J.: Nucleosides XLVIII. Synthesis of 1 -(5-deoxy-D-arabinosy 1) cytosine and related compounds. J. med. Chem. 11, 148–151 (1968).PubMedGoogle Scholar
  60. Feldman, L. A., Rapp, F.: Inhibition of adenovirus replication by 1-β-D-arabinofuranosyl-cytosine. Proc. Soc. exp. Biol. (N.Y.) 122, 243–247 (1966).Google Scholar
  61. Finkelstein, J. Z., Scher, J., Karon,M.: Pharmacologic studies of tritiated cytosine arabinoside (NSC-63878) in children. Cancer Chemother. Rep. 54, 35–39 (1970).Google Scholar
  62. Fischer, D. S., Cassidy, E. P., Welch, A. D.: Immunosuppression by pyrimidine nucleoside analogs. Biochem. Pharmacol. 15, 1013–1022 (1966).PubMedGoogle Scholar
  63. Flickinger,R.A.: Delay of normal development of sea urchin embryos by cytosine arabinoside. Experientia (Basel) 23, 136 (1967).Google Scholar
  64. Fox, J. J., Yung, N., Bendich, A.: Pyrimidine nucleosides. II. The synthesis of 1-β-D-arabino-furanosylthymine (spongothymidine). J. Amer. chem. Soc. 79, 2775–2778 (1957).Google Scholar
  65. Furlong, N. B., Gresham, C.: Inhibition of DNA synthesis but not of poly-DAT synthesis by the arabinose analogue of cytidine in vitro. Nature (Lond.) 233, 212–214 (1971).Google Scholar
  66. Furth, J. J., Cohen, S. S.: Inhibition of mammalian DNA polymerase by the 5’-triphosphate of 1-β-D-arab inof uranosy ladenine. Cancer Res. 27, 1528–1533 (1967).PubMedGoogle Scholar
  67. Furth, J. J., Cohen, S. S.: Effect of the 5’-triphosphates of 1-β-D-arabinof uranosylcytosine and 1-β-D-arabinofuranosyladenine on the enzymatic synthesis of nucleic acid in mammalian tissues. Proc. Amer. Ass. Cancer Res. 9, 23 (1968 a).Google Scholar
  68. Furth, J. J., Cohen, S. S.: Inhibition of mammalian DNA polymerase by the 5’-triphosphate of 1-JFT-D-arabinofuranosylcytosine and the 5’-triphosphate of 1-β-D-arabinofuranosyl- adenine. Cancer Res. 28, 2061–2067 (1968b).PubMedGoogle Scholar
  69. Gish, D. T., Neil, G. L., Wechter, W. J.: Nucleic acids. 12. Synthesis of the L–enantiomer of 1 –β-D-arabinof uranosy Icy tosine and of 02, 02’-anhydro-1-β-D-arabinofuranosylcytosine. J. med. Chem. 14, 882–883 (1971).PubMedGoogle Scholar
  70. Giziewicz, J., Kuśmierek, J.T., Shugar, D.: 5’-O-Methyl derivatives of 1-β-D-arabinofuran- osylcytosine and 1-β-D-arabinofuranosyluracil. J. med. Chem. 15, 839–840 (1972).Google Scholar
  71. Goldenberg, D. M.: Oral activity of 1-β-D-arabinofuranosyl cytosine in a transplantable hamster melanoma. Chemotherapy 16, 294–299 (1971).PubMedGoogle Scholar
  72. Graham, F. L., Whitmore, G. F.: Studies in mouse L-cells on the incorporation of 1-β-D- arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D- arabinofuranosylcytosine-5’-triphosphate. Cancer Res. 30, 2636–2644 (1970a).PubMedGoogle Scholar
  73. Graham, F.L., Whitmore,G.F.: The effect of 1-β-D-arabinofuranosylcytosine on growth, viability and DNA synthesis of mouse L-cells. Cancer Res. 30, 2627–2635 (1970b).PubMedGoogle Scholar
  74. Gray, G. D., Nichol. R., Miokelson, M. M., Camiener, G. W., Gish, D. T., Kelly, R. C., Wech-Ter, W. J., Moxley, T. E., Neil, G. L.: Immunosuppressive, antiviral and antitumor activities of cytarabine derivatives. Biochem. Pharmacol. 21, 465–475 (1972).PubMedGoogle Scholar
  75. Greenstein, J. P., Carter, C. E., Chalkley, H. W.: Enzymatic degradation of ribose-nucleic and desoxyribosenucleic acids with an addendum on the effect of nucleates on the heat stability of proteins. Cold Spr. Harb. Symp. Quant. Biol., 12, 64 (1947).Google Scholar
  76. Grindey, G. B., Saslaw, L. D., Waravdekar, V. S.: Relationship of uracil derivatives to the metabolism of arabinosylcytosine (ara-C). Proc. Amer. Ass. Cancer Res. 8, 24 (1967).Google Scholar
  77. Grindey, G. B., Saslaw, L. D., Waravdekar, V. S.: Effects of uracil derivatives on phosphorylation of arabinosylcytosine. Molec. Pharmacol. 4, 96–103 (1968).Google Scholar
  78. Griswold, D. P., Jr., Simpson-Herren, L., Schabel, F. M., Jr.: Altered sensitivity of a hamster plasmacytoma to cytosine arabinoside (NSC-63878). Cancer Chemother. Rep. 54, 337 –346 (1970).PubMedGoogle Scholar
  79. Hall, T. C., Levine, R.: Deamination of cytosine arabinoside by normal and malignant tissues. Proc. Amer. Ass. Cancer Res. 8, 24 (1967).Google Scholar
  80. Hanka, L. J., Kuentzel, S. L., Neil, G. L.: Improved microbiological assay for cytosine arabinoside (NSC-63878). Cancer Chemother. Rep. 54, 393–397 (1970).Google Scholar
  81. Hanze, A. R.: Nucleic acids. IV. The catalytic reduction of pyrimidine nucleosides (human liver deaminase inhibitors). J. Amer. chem. Soc. 89, 6720–6725 (1967).Google Scholar
  82. Haus, E., Halberg, F., Scheving, L. E., Pauly, J. E., Cardoso, S., Kuhl, J. F. W., Sothern, R.B., Shiotsuka, R. N., Hwang, D. S.: Increased tolerance of leukemic mice to arabinosylcytosine with schedule adjusted to circadian system. Science 177, 80–82 (1972).PubMedGoogle Scholar
  83. Heneen, W. K., Nichols, W. W.: Cell morphology of a human diploid cell strain (WI-38) after treatment with arabinosylcytosine. Cancer Res. 27, 242–250 (1967).PubMedGoogle Scholar
  84. Heppner, G. H., Calabresi,P.: Suppression by cytosine arabinoside of serum-blocking factors of cell-mediated immunity to syngeneic transplants of mouse mammary tumors. J. nat. Cancer Inst. 48, 1161–1167 (1972).PubMedGoogle Scholar
  85. Hirschman, S. Z., Fischinger, P. J., O’connor, T. E.: The inhibition by cytosine arabinoside of the replication of murine leukemia and sarcoma viruses in mouse embryo cultures. J. Cancer 4, 671–677 (1969).Google Scholar
  86. Ho, D. H. W., Frei, E., ILL: Clinical pharmacology of 1 D-arabinofuranosyIcytosine. Clin. Pharmacol. Therap. 12, 944–954 (1971).Google Scholar
  87. Ho, D. H. W., Freireioh, E. J.: Clinical pharmacology of arabinosylcytosine. In: Sartorelli, A. C., Johns, D. J. (Eds.): Handbook of experimental pharmacology, Vol. 38. Antineoplastic and immunosuppressive agents. Berlin-Heidelberg-New York: Springer 1975.Google Scholar
  88. Hoshi, A., Kanzawa, F., Kuretani, K., Saneyoshi, M., Arai,Y.: 2,2’-o-Cyclocytidine, antitumor cytidine analog resistant to cytidine deaminase. Gann 02, 145–146 (1971).Google Scholar
  89. Hunt, D. E., Pittillo, R. F.: Determination of certain antitumor agents in mouse blood by microbiologic assay. Cancer Res. 28, 1095–1109 (1968).PubMedGoogle Scholar
  90. Hunter, J. H.: Transforming 1-β-D-xylofuranosyluracil nucleosides into 1-β-D-arabinofurano- syluracil nucleosides. U.S. Patent 3, 183, 226, May 11, 1965, in Chem. Abstr. 03, 16446g (1965).Google Scholar
  91. Inagaki, A., Naeamura, T., Wakisaka, G.: Studies on the mechanism of action of 1- β -D- arabinofuranosy Icy tosine as an inhibitor of DNA synthesis in human leukemic leukocytes. Cancer Res. 29, 2169–2176 (1969).PubMedGoogle Scholar
  92. Kanai, T., Kojima, T., Maruyama, O., Ichino, M.: Pyrimidine nucleosides. III. Reaction of cytidine or N-4-acetylcytidine with partially hydrolyzed phosphorous oxychloride. Chem. pharm. Bull. (Tokyo) 18, 2569–2570 (1970).Google Scholar
  93. Kaplan, A. S., Brown, McK., Ben-Porat, T.: Effect of 1-β-D-arabinofuranosylcytosine on DNA synthesis I. In normal rabbit kidney cell cultures. Molec. Pharmacol. 4, 131–138 (1968).Google Scholar
  94. Karnofsky, D. A., Lacon, C. R.: The effects of 1-β-D-arabinofuranosylcytosine on the developing chick embryo. Biochem. Pharmacol. 15, 1435–1442 (1966).PubMedGoogle Scholar
  95. Karon, M., Henry, P., Weissman, S., Meyer, C.: The effect of 1-β-d-arabinofuranosyl cytosine on macromolecular synthesis in KB spinner cultures. Cancer Res. 26, 166–171 (1966).PubMedGoogle Scholar
  96. Karon, M., Shirakawa,S.: The locus of action of 1-β-d-arabinofuranosylcytosine in the cell cycle. Cancer Res. 29, 687–696 (1969).PubMedGoogle Scholar
  97. Kessel, D.: Transport and phosphorylation of cytosine arabinoside by normal and leukemic cells. Proc. Amer. Ass. Cancer Res. 8, 36 (1967).Google Scholar
  98. Kessel,D.: Some observations on the phosphorylation of cytosine arabinoside. Molec. Pharmacol. 4, 402–410 (1968a).Google Scholar
  99. Kessel,D.: Properties of deoxycytidine kinase partially purified from L1210 cells. J. biol. Chem. 243, 4739–4744 (1968b).Google Scholar
  100. Kessel, D., Hall, T. C.: Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 156, 1240–1241 (1967).PubMedGoogle Scholar
  101. Kessel, D., Hall, T. C., Rosenthal, P.: Uptake and phosphorylation of cytosine arabinoside by normal and leukemic blood cells in vitro. Cancer Res. 29, 459–463 (1969).PubMedGoogle Scholar
  102. Kessel, D., Hall, T. C., Wodinsky, I.: Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 156, 1240–1241 (1967).PubMedGoogle Scholar
  103. Kessel, D., Shttrin, S. B.: Transport of two non-metabolized nucleosides, deoxycytidine and cytosine arabinoside, in a sub-line of the L1210 murine leukemia. Biochim. biophys. Acta (Amst.) 163, 179–187 (1968).Google Scholar
  104. Kihlman, B. A., Nichols, W. W., Levan, A.: The effect of deoxyadenosine and cytosine arabinoside on the chromosomes of human leukocytes in vitro. Hereditas 50, 139–143 (1963).Google Scholar
  105. Kim, J. H., Eidinoff, M. L.: Action of 1-β-d-arabinofuranosylcytosine on the nucleic acid metabolism and viability of HeLa cells. Cancer Res. 25, 698–702 (1965).PubMedGoogle Scholar
  106. Kim, J. H., Eidinoff, M. L., Fox, J. J.: Action of 1-β-D-arabinofuranosyl-5-fluorocytosine on the nucleic acid metabolism and viability of HeLa cells. Cancer Res. 26, 1661–1664 (1966).PubMedGoogle Scholar
  107. Kimball, A. P., Bowman, B., Bush, P. S., Herriot, J., LePage, G. A.: Inhibitory effects of the arabinosides of 6-mercaptopurine and cytosine on purine and pyrimidine metabolism. Cancer Res. 26, 1337–1343 (1966).PubMedGoogle Scholar
  108. Kimball. A. P., Wilson, M. J.: Inhibition of DNA polymerase by 1-β-D-arabinosylcytosine and reversal of inhibition by deoxycytidine-5’ -triphosphate. Proc. Soc. exptl. Biol. (N.Y.) 127, 429–432 (1968).Google Scholar
  109. Kit, S., DeTorres, R. A., Dubbs, D. R.: Arabinofuranosylcytosine-induced stimulation of thymidine kinase and deoxycytidylic deaminase activities of mammalian cultures. Cancer Res. 26, 1859–1866 (1966).PubMedGoogle Scholar
  110. Kline, I., Venditti, J. M., Tyrer, D. D.; Goldin, A.: Chemotherapy of leukemia L1210 in mice with 1-β-D-arabinofuranosylcytosine hydrochloride I. Influence of treatment schedules. Cancer Res. 26, 853–859 (1966).PubMedGoogle Scholar
  111. Kozai, Y.. Sugino, Y.: Enzymatic phosphorylation of 1-β-D-arabinofuranosylcytosine. Cancer Res. 31, 1376–1382 (1971).Google Scholar
  112. Kreis, W., Drahovsky, D., Borberg, H.: Characterization of protein and DNA in P815 cells sensitive and resistant to 1-β-d-arabinofuranosylcytosine. Cancer Res. 32, 696–701 (1972).PubMedGoogle Scholar
  113. Larsson, A., Reichard, P.: Enzymatic synthesis of deoxyribonucleotides X. Reduction of purine ribonucleotides; allosteric behavior and substrate specificity of the enzyme system from Escherichia coli B. J. biol. Chem. 241, 2540–2549 (1966).PubMedGoogle Scholar
  114. Lenaz, L., Sternberg, S. S., Philips, F. S.: Cytotoxic effects of 1-β-d-arabinofuranosy 1-5- fluorocytosine and of 1-β-d-arabinofuranosyIcytosine in proliferating tissues in mice. Cancer Res. 29, 1790–1798 (1969).PubMedGoogle Scholar
  115. Livingston, R. B., Carter, S. K.: Cytosine arabinoside (NSC-63878)-clinical brochure. Cancer Chemother. Rep. 1, 179–205 (1968).Google Scholar
  116. Loh, P. C., Soergel, M.: Macromolecular synthesis in cells infected with reovirus type 2 and the effect of ara-C. Nature (Lond.) 214, 622–623 (1967).Google Scholar
  117. Mitchell, M. S., Wade, M. E., DeConti, R. C., Bertino, J. R., Calabresi, P.: Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Ann. intern. Med. 70, 535 –547 (1969).PubMedGoogle Scholar
  118. Momparler, R. L.: Kinetic and template studies with 1-β-d-arabinofuranosylcytosine 5’-tri- phosphate and mammalian deoxyribonucleic acid polymerase. Molec. Pharmacol. 8, 362–370 (1972).Google Scholar
  119. Momparler, R. L., Chu, M. Y., Fischer, G. A.: Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim. biophys. Acta (Amst.) 161, 481–493 (1968).Google Scholar
  120. Momparler, R. L., Fischer, G. A.: Mammalian deoxynucleoside kinases I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J. biol. Chem. 243, 4298–4304 (1968).PubMedGoogle Scholar
  121. Momparler, R. L., Labitan, A., Rossi, M.: Enzymatic estimation and metabolism of 1-β-d- arabinofuranosylcytosine in man. Cancer Res. 32, 408–412 (1972).PubMedGoogle Scholar
  122. Montgomery, J. A., Thomas, H. J.: Acyl derivatives of 1-β-D-arabinofuranosyl cytosine. J. med. Chem. 15, 116–118 (1972).PubMedGoogle Scholar
  123. Moore, E. C., Cohen, S. S.: Effects of arabinonucleotides on ribonucleotide reduction by an enzyme system from rat tumor. J. biol. Chem. 242, 2116–2118 (1967).PubMedGoogle Scholar
  124. Müller, W. E. G., Yamazak, Z. I., Sögtrop, H. H., Zahn, R. K.: Action of 1-β-D-arabinofuran-osylcytosine on mammalian tumor cells-2. Inhibition of mammalian and oncogenic viral polymerases. Europ. J. Cancer 8, 421–428 (1972).Google Scholar
  125. Mulligan, L.T., Jr., Mellett, L. B.: Comparative metabolism of cytosine arabinoside and inhibition of deamination by tetrahydrouridine. Pharmacologist 10, 167 (1968).Google Scholar
  126. Neil, G. L., Weley, P. F., Manak, R. C., Moxley, T. E.: Antitumor effect of 1-β-D-arabino-furanosylcytosine 5’-adamantoate (NSC-117614) in leukemic mice. Cancer Res. 30, 1047– 1054 (1970).Google Scholar
  127. Nordenskjöld, B. A., Skoog, L., Brown, N. C., Reichard,P.: Deoxyribonucleotide pools and deoxyribonucleic acid synthesis in cultured mouse embryo cells. J. biol. Chem. 245, 5360 –5368 (1970).PubMedGoogle Scholar
  128. Notari, R. E.: A mechanism for the hydrolytic deamination of cytosine arabinoside in aqueous buffer. J. pharm. Sci. 56, 804–809 (1967).PubMedGoogle Scholar
  129. Notari, R. E., Chin, M. L., Wittebort,R.: Arabinosylcytosine stability in aqueous solutions: pH profile and shelflife predictions. J. pharm. Sci. 61, 1189–1196 (1972).PubMedGoogle Scholar
  130. Nutter, R.L., Rapp, F.: The effect of cytosine arabinoside on virus production in various cells infected with herpes simplex virus types 1 and 2. Cancer Res. 33, 166–170 (1973).PubMedGoogle Scholar
  131. Panzica,R.P., Robins, R.K., Townsend,L.B.: Synthesis and anticancer activity of cytosine arabinoside 3-N-oxide (ara-C 3-N-oxide). J. med. Chem. 14, 259 (1971).Google Scholar
  132. Papac,R.J., Calabresi,P., Hollingsworth,J.W., Welch,A.D.: Effects of 1-0-D-arabino- furanosylcytosine hydrochloride on regenerating bone marrow. Cancer Res. 25, 1459–1462 (1965).Google Scholar
  133. Papac, R. J., Creasey, W. A., Calabresi, P., Welch, A. D.: Clinical and pharmacological studies with 1-β-D-arabinofuranosylcytosine (cytosine arabinoside). Proc. Amer. Ass. Cancer Res. 6, 50 (1965).Google Scholar
  134. Pearson, P. M., Kit, S., Dubbs, D. R.: Induction of dihydrofolate reductase by SV40 and polyoma virus. Cancer Res. 26, 1653–1660 (1966).Google Scholar
  135. Peterkofsky, B., Tomkins, G. sM.: Effect of inhibitors of nucleic acid synthesis on steroid-mediated induction of tyrosine aminotransferase in hepatoma cell cultures. J. molec. Biol. 80, 49–61 (1967).Google Scholar
  136. Pitillo, R. F., Hunt, D. E.: Cytosine arabinoside sensitivity in actinobolin-resistant Streptococcus fecalis: the basis of a utilitarian microbiological assay. Proc. Soc. exp. Biol. (N.Y.) 124, 636–640 (1967).Google Scholar
  137. Pizer, L. I., Cohen, S. S.: Metabolism of pyrimidine arabinonucleotides and cyclonucleosides in Escherichia coli. J. biol. Chem. 235, 2387–2392 (1960).PubMedGoogle Scholar
  138. Rama Reddy, G. V., Goulian, M., Hendler, S. S.: Inhibition of E. coli DNA polymerase II by ara CTP. Nature (Lond.) 234, 286–288 (1971).Google Scholar
  139. Reichard, P., Cannalakis, Z. N., Cannalakis, E. S.: Studies on a possible regulatory mechanism for the biosynthesis of deoxyribonucleic acid. J. biol. Chem. 236, 2514–2519 (1961).PubMedGoogle Scholar
  140. Renis, H. E., Johnson, H.G.: Inhibition of plaque formation of vaccinia virus by cytosine arabinoside hydrochloride. Bacterid. Proc. 140 (1962).Google Scholar
  141. Ritter, E. J., Scott, W. J., Wilson, J. G.: Teratogenesis and inhibition of DNA synthesis induced in rat embryos by cytosine arabinoside. Teratology 4, 7–14 (1971).PubMedGoogle Scholar
  142. Roberts, D. W., Hall,T. C., Rosenthal, D.: Sequential changes in biochemical parameters following cytosine arabinoside administration. Proc. Amer. Ass. Cancer Res. 9, 60 (1968).Google Scholar
  143. Roberts, D.W., Loehr, E. V.: Methotrexate and cytosine arabinoside modulation of thymidyl- ate synthetase activity in CCRF-CEM cells. Cancer Res. 31, 457–462 (1971).Google Scholar
  144. Roberts, W. K., Dekker, C. A.: A convenient synthesis of arabinosylcytosine (cytosine arabinoside). J. org. Chem. 32, 816–817 (1967).PubMedGoogle Scholar
  145. Russell, D. H.: Effects of me thotrexate and cytosine arabinoside on polyamine metabolism in a mouse L1210 leukemia. Cancer Res. 32, 2459–2462 (1972).PubMedGoogle Scholar
  146. Sartorelli, A. C., Creasey, W. A.: Cancer Chemotherapy. Ann. Rev. Pharmacol. 9, 51–72 (1969).PubMedGoogle Scholar
  147. Sartorelli, A. C., Creasey,W. A.: Combination chemotherapy. In: Holland,J. F., Frei,E. III (Eds.): Cancer medicine, pp. 707–717. Philadelphia: Lea and Febiger 1973.Google Scholar
  148. Schabel, F. M., Jr.: In vivo leukemia cell kill kinetics and “curability” in experimental systems. In: The proliferation and spread of neoplastic cells, pp. 379–408. Baltimore: Williams and Wilkins 1968.Google Scholar
  149. Schmidt, G.: Über den fermentativen Abbau der Guanylsäure in der Kaninchenleber. Hoppe-Seyler Z. physiol. Chem. 208, 185–224 (1932).Google Scholar
  150. Schochetman, G., Perry, R. P.: Early appearance of histone messenger RNA in polyribosomes of cultured L cells. J. molec. Biol. 63, 591–596 (1972).Google Scholar
  151. Schrecker, A. W.: Metabolism of 1-β-D-arabinofuranosyIcytosine in leukemia L1210: nucleoside and nucleotide kinases in cell-free extracts. Cancer Res. 30, 632–641 (1970).PubMedGoogle Scholar
  152. Schrecker, A. W., Goldin, A.: Antitumor effect and mode of action of 1-β-D-arabinofuranosyl-cytosine 5’-phosphate in leukemia L1210. Cancer Res. 28, 802–803 (1968).PubMedGoogle Scholar
  153. Schrecker, A. W., Urshel, M. J.: Nucleoside kinases in leukemia L1210 and a subline resistant to arabinosylcytosine. Proc. Amer. Ass. Cancer Res. 8, 58 (1967).Google Scholar
  154. Schrecker, A. W., Urshel,M.J.: Metabolism of 1-β-D-arabinofuranosylcytosine in leukemia L1210: studies with intact cells. Cancer Res. 28, 793–801 (1968).Google Scholar
  155. Silagi, S.: Metabolism of 1-β-D-arabinof uranosylcy tosine in L cells. Cancer Res. 25, 1446–1453 (1965).PubMedGoogle Scholar
  156. Skipper, H. E., Schabel, F. M., Jr., Mellett, L. B., Montgomery, J. A., Wilkoff, L. J., Lloyd, H. H., Brockman, R.W.: Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic studies. Cancer Chemother. Rep. 54, 431–449 (1970).Google Scholar
  157. Skipper, H. E., Schabel, F. M., Jr., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother. Rep. 51, 125–165 (1967).Google Scholar
  158. Skoog, L., Nordenskjold, B.: Effects of hydroxyurea and 1-β-D-arabinof uranosylcytosine on deoxyribonucleotide pools in mouse embryo cells. Europ. J. Biochem. 19, 81–89 (1971).PubMedGoogle Scholar
  159. Slechta, L.: Effect of arabonucleosides on growth and metabolism of E. coli. Fed. Proc. 20, 357 (1961).Google Scholar
  160. Smith, C. G., Buskirk, H. H., Lummis, W. L.: Effect of arabinofuranosyluracil on the cytotoxicity of arabinofuranosylcytosine in PPLO-contaminated cell cultures. Proc. Amer. Ass. Cancer Res. 6, 60 (1965).Google Scholar
  161. Smith, D. B., Chu, E. H. Y.: A genetic approach to the study of cytotoxicity and resistance of cultured Chinese hamster cells in the presence of cytosine arabinoside. Cancer Res. 32, 1651–1657 (1972).PubMedGoogle Scholar
  162. Smrt, J.: Nucleic acid components and their analogues. C. Arabinof uranosyluracil and arabino-furanosylcytosine phosphates. Coll. Czech. Chem. Commun. 32, 3958–3965 (1967).Google Scholar
  163. Steuart, C. D., Burke, P. J.: Cytidine deaminase and the development of resistance to arabinosylcytosine. Nature (Lond.) 233, 109–110 (1971).Google Scholar
  164. Steuart, C. D., Burke, P. J., Owens, A. H., Jr.: Correlation of ara-C metabolism and clinical response in adult acute leukemia. Proc. Amer. Ass. Cancer Res. 12, 89 (1971).Google Scholar
  165. Talley, R.W., O’bryan, R. M., Tucker, W. G., Loo, R. V.: Clinical pharmacology and human antitumor activity of cytosine arabinoside. Cancer 20, 809–816 (1967).PubMedGoogle Scholar
  166. Talley, R., Vaitkevtcius, V.: Megaloblastosis produced by a cytosine antagonist, 1-β-D- arabinofuranosylcytosine, Blood 21, 352–362 (1963).PubMedGoogle Scholar
  167. Temin, H. M.: Studies on carcinogenesis by avian sarcoma viruses. V. Requirement for new DNA synthesis and for cell division. J. Cell Physiol. 69, 53–64 (1967).Google Scholar
  168. Tobey, R. A.: Effects of cytosine arabinoside, daunomycin, mithramycin, azacytidine, adriamycin, and camptothecin on mammalian cell cycle traverse. Cancer Res. 32, 2720–2725 (1972).PubMedGoogle Scholar
  169. Tolman, R. L., Robins, R. K.: Synthesis of l-β-L-arabinof uranosylcy tosine, the enantiomer of cytosine arabinoside. J. med. Chem. 14, 1112 (1971).PubMedGoogle Scholar
  170. Tono, H., Cohen, S. S.: The activity of nucleoside phosphorylase on 1-β-D-arabinosyluracil within Escherichia colu J. biol. Chem. 237, 1271–1282 (1962).PubMedGoogle Scholar
  171. Tuominen, F. W., Kenney, F. T.: Inhibition of RNA-directed DNA polymerase from Rauscher leukemia virus by the 5’-triphosphate of cytosine arabinoside. Biochem. biophys. Res. Commun. 48, 1469–1475 (1972).Google Scholar
  172. Tyrer, D. D., Kline, I., Venditti, J. M., Goldin, A.: Separate and sequential chemotherapy of mouse leukemia L1210 with 1-β-D-arabinof uranosylcy tosine hydrochloride and 1, 3-bis- (2-chloroethyl)nitrosourea. Cancer Res. 27, 873–879 (1967).Google Scholar
  173. Uchida,K., Kreis,W., Hutchison, D. J.: Distribution of 1-β-D-arabinof uranosy Icy tosine (ara-C) and enzyme profiles of mice carrying ara-C-sensitive and -resistant P815 neoplasms. Proc. Amer. Ass. Cancer Res. 9, 72 (1968).Google Scholar
  174. Underwood, G. E.: Activity of 1- β-D-arabinofuranosylcytosine hydrochloride against herpes simplex keratitis. Proc. Soc. exp. Biol. (N. Y.) III, 660–664 (1962).Google Scholar
  175. Upjohn Company: Cytarabine (Cytosar). Clin. Pharmacol. Therap. 11, 155–160 (1970).Google Scholar
  176. Verbin, R. S., Diluiso, G., Liang, H., Farber, E.: Synchronization of cell division in vivo through the combined use of cytosine arabinoside and colcemid. Cancer Res. 32, 1489–1495 (1972).PubMedGoogle Scholar
  177. Walwick, E. R., Roberts, W. K., Dekker, C. A.: Cyclization during the phosphorylation of uridine and cytidine by polyphosphoric acid; a new route to the 02, 2’-cyclonucleosides. Proc. chem. Soc. 84 (1959).Google Scholar
  178. Warner, D. T., Neil, G. L., Taylor, A. J., Weohter, W. J.: Nucleic acids. 13. 3’-0- and 2’-0- esters of 1 -β-D-arabinofuranosylcytosine as antileukemic and immunosuppressive agents. J. med. Chem. 15, 790–792 (1972).PubMedGoogle Scholar
  179. Wempen, I., Miller, N., Falco, E. A., Fox, J. J.: Nucleosides XLVII. Synthesis of some N4- substituted derivatives of 1-β-D-arabinofuranosyl-cytosine and -5-fluorocytosine. J. med. Chem. 11, 144–148 (1968).PubMedGoogle Scholar
  180. Wilkoff, L. J., Wilcox, W. S., Burdeshaw, J. A., Dixon, G. J., Dulmadge, E. A.: Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells. J. nat. Cancer Inst. 89, 965–975 (1967).Google Scholar
  181. Wodinsky, I., Kensler, C. J.: Activity of cytosine arabinoside (NSC-63878) in a spectrum of rodent tumors. Cancer Chemother. Rep. 47, 65–68 (1965).Google Scholar
  182. Young, C.W., Hodas, S.: Acute effects of cytotoxic compounds on incorporation of precursors into DNA, UNA, and protein of HeLa cell monolayers. Biochem. Pharmacol. 14, 205–214 (1965).PubMedGoogle Scholar
  183. Young, R. S. K., Fischer, G. A.: The action of arabinosylcytosine on synchronously growing populations of mammalian cells. Biochem. biophys. Res. Commun. 32, 23–29 (1968).Google Scholar
  184. Zahn, R. K., Muller, W. E. G., Forster, W., Maidhof, A., Beyer, R.: Action of 1-β-D-arabino- furanosylcytosine on mammalian tumor cells-1. Incorporation into DNA. Europ. J. Cancer 8, 391–396 (1972).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1975

Authors and Affiliations

  • William A. Creasey

There are no affiliations available

Personalised recommendations